BRAF and melanoma: To date, interferon-alfa (IFN), ipilimumab (ipi) and nivolumab have achieved regulatory approvals for the adjuvant treatment of high-risk melanoma following surgical management, while the combination of dabrafenib and trametinib was granted a breakthrough therapy designation by the Food and Drug Administration for stage III melanoma with a BRAF V600 mutation [1].